Featured Cancer Vaccine Type

Creative Biolabs provides comprehensive, end-to-end cancer vaccine type development services, covering cutting-edge modalities such as neoantigen, tumor cell, dendritic cell, nucleic acid (DNA/mRNA), and viral vectors. We are dedicated to overcoming the challenges of tumor immune evasion through customized, highly immunogenic vaccine design and high-standard research-use product manufacturing support. Our goal is to accelerate the transition of your cancer immunotherapy research from antigen discovery to effective preclinical proof-of-concept.

Cancer Vaccine Types and Key Considerations

A cancer vaccine is a biological agent designed to utilize a patient's own immune system to specifically recognize and attack cancer cells. Based on function, they are mainly categorized into prophylactic vaccines and therapeutic vaccines. The core principle of therapeutic cancer vaccines is to introduce tumor-specific antigens to elicit a robust cytotoxic t lymphocyte response, thereby achieving long-term, specific anti-tumor immune memory.

Key Challenges and Considerations in Cancer Vaccine Development

Tumor Heterogeneity

The high variability of antigen expression within a tumor is a major obstacle. This demands that vaccines cover multiple tumor-associated antigens (TAAs) or target patient-specific neoantigens.

Suppression by the Tumor Microenvironment

The TME is often rich in immunosuppressive cells and factors. A successful vaccine must be able to penetrate this barrier or be combined with agents like immune checkpoint inhibitors to enhance efficacy.

Antigen Selection and Delivery Systems

It is essential to select highly immunogenic antigens and pair them with efficient and safe delivery systems to ensure effective antigen presentation to immune cells.

How Creative Biolabs Empowers Your Project

Addressing Target Specificity Challenges

Core Types: Neoantigen/Peptide Vaccines
Solution: By custom synthesizing neoantigen peptides, we precisely bypass the challenge of tumor heterogeneity, directly targeting patient-specific mutations to ensure highly specific immune responses.

Overcoming Immune Presentation Inefficiency

Core Types: Dendritic Cell (DC) Vaccines, Nucleic Acid Vaccines (DNA/mRNA Vaccines)
Solution: DC vaccines use specialized cells for potent T-cell priming. Nucleic acid vaccines (LNP/plasmid) enable massive antigen expression in host cells, overcoming the low presentation bottleneck of traditional protein vaccines.

Solving Insufficient In Vivo Immunogenicity

Core Types: Vector-based Vaccines, Tumor Cell Vaccines
Solution: Viral/bacterial vectors provide a natural adjuvant effect, greatly enhancing immune stimulation; tumor cell vaccines provide all tumor antigens at once, especially unknown or low-abundance ones, to elicit a broader and more durable immune response.

Detailed Cancer Type Services

Neoantigen Cancer Vaccine Development	Tumor Cell Vaccine Development
Dendritic Cell Vaccine Development	Antigen Vaccine Development
Anti-Idiotype Vaccine Development	DNA based Cancer Vaccine Development
mRNA based Cancer Vaccine Development	Vector based Vaccine Development
Fully Synthetic Carbohydrate based Cancer Vaccine Development	BCG Vaccine Development
Ty21 based Vaccine Development	Exosome based Therapeutic Cancer Vaccine Development
Ag-Fc Fusion Protein based Vaccine Development	Biomaterial-based Implantable Cancer Vaccine Development
Cytomegalovirus based Cancer Immunotherapy Development	Immunological Checkpoint Therapy Development
Immunoplacental Therapy Development	Antibody Inducing Polyvalent Cancer Vaccine Development

Platforms and Technologies

Neoantigen Precision Prediction Platform

Combines AI/machine learning algorithms with high-throughput sequencing data to efficiently screen for MHC Class I and Class II binding neoantigens.

High-Performance Viral/Bacterial Vector Engineering

Performs gene editing and optimization for various vectors, including Ad, AAV, MVA, and listeria, to achieve highly efficient in vivo delivery.

Automated DC Vaccine Preparation System

Supports scalable isolation, culture, antigen pulsing, and final product preparation of dendritic cells (DCs) for non-clinical research use.

Multi-Parameter Immunology Analysis Platform

Includes flow cytometry, tetramer staining, and cytokine profiling for comprehensive assessment of vaccine immunogenicity.

Standardized Development Workflow

Target Discovery and Screening

Steps: Tumor sample collection and analysis, high-throughput sequencing, TCR/BCR repertoire analysis, and Neoantigen prediction.
Deliverable: Verified tumor-specific antigens or neoantigen sequences.

Vaccine Design and Construction

Steps: Selection of vaccine type (mRNA, DC, Vector, etc.), gene synthesis/cell preparation, vector construction, adjuvant selection and optimization.
Deliverable: Optimized vaccine constructs (plasmid, mRNA molecule, or pulsed DC cells).

Formulation and Process Development

Steps: Optimization of delivery systems (LNP, emulsion, etc.), small-scale process development, scale-up procedures, and stability testing.
Deliverable: Stable, efficient vaccine formulation protocols and production SOPs.

Pre-clinical Evaluation

Steps: In vitro immunogenicity testing, in vivo pharmacodynamics (PD) and pharmacokinetics (PK) studies in animal models, and non-GLP exploratory toxicology and safety assessment.
Deliverable: Comprehensive high-quality preclinical research report, strictly for research purposes.

Partner with Creative Biolabs Now!

Creative Biolabs Advantages in Cancer Vaccine

Complete Type Coverage

Offers the widest range of cancer vaccine type development options, from traditional cell-based to cutting-edge nucleic acid and biomaterial-based vaccines, meeting any complex project requirement.

Leading Neoantigen Technology

Possesses an industry-leading Neoantigen precision prediction and synthesis platform, which is key to customized cancer vaccine development.

High-Standard Research Production

Equipped with high-standard facilities to provide high-quality non-clinical grade DNA, mRNA, and cell products, strictly controlling the quality and batch stability of research-use products.

Experienced Expert Team

The core team consists of dozens of experts with an average of over 10 years of experience in immunology and vaccinology, ensuring the professionalism and foresight of technical guidance.

A slide highlighting the advantages of Creative Biolabs in the context of featured cancer vaccine types.

Customer Reviews

"Creative Biolabs demonstrated outstanding LNP formulation capabilities in our highly complex mRNA cancer vaccine project. Their customized LNPs significantly increased our antigen expression levels and in vivo stability, successfully helping us efficiently complete the preclinical proof-of-concept. They are true partners."

— David L.,

R&D Director, Biotechnology Company

"We faced challenges with scalable cell expansion and pulsing efficiency while developing a novel DC vaccine. Creative Biolabs' automated DC preparation platform not only solved the production bottleneck but also provided impeccable quality control. Highly recommended to all our peers in cell therapy."

— Emily Chen,

Principal Scientist, Cancer Research Institute

"Antigen synthesis in our anti-idiotype vaccine project was extremely challenging. Creative Biolabs provided high-quality custom synthesis and purification services, along with detailed analytical reports, ensuring the accuracy of our subsequent immunological experiments."

— Dr. F. Ruiz,

Immunology Program Lead

Case Study

HBV Synthetic Long Peptide (SLP)-Pulsed Dendritic Cell (DC) Cancer Vaccine

Background

A study aimed to explore DCs pulsed with 12 HBV-based SLPs (plus TLR1/2 ligand or TLR3 ligand polyinosinic-polycytidylic acid) for therapeutic vaccine design, addressing limited insights into SLP cross-presentation and adjuvant effects on DC HLA-I immunopeptidome.

Solution

MoDCs from 6 HLA-A02:01/A11:01-matched donors were loaded with SLPs + adjuvants. HLA-I peptides were analyzed via LC-MS/MS (DDA/DIA). T2 cell assay validated HLA binding; STRING/GO analyzed adjuvant-specific proteins.

Result

33 unique SLP-derived HLA-I peptides (14 novel) were identified, with HLYSHPIIL/G (HLA-A2 binders) across donors. Adjuvants didn't affect SLP cross-presentation but TLR3 ligand induced antiviral proteins. DC immunopeptidomics proved valuable for DC vaccine design, aiding SLP/adjuvant selection.

A slide displaying a schematic overview of Modc (Modified Dendritic Cell) generation and SLP (Synthetic Long Peptide) loading.

Schematic Overview of Modc Generation and SLP Loading.
Kessler, Amy L., et al. "HLA I immunopeptidome of synthetic long peptide pulsed human dendritic cells for therapeutic vaccine design." npj Vaccines 10.1 (2025): 12. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1038/s41541-025-01069-1

Frequently Asked Questions

Can Creative Biolabs support the development of multiple cancer vaccine types simultaneously?

Yes. We offer comprehensive cancer vaccine development services covering cell-based (e.g., DC vaccines), nucleic acid-based (DNA/mRNA vaccines), vector-based, and protein/peptide-based vaccines. We can flexibly select or combine multiple technological routes based on your targets and project goals.

What is the typical development timeline for a personalized Neoantigen vaccine?

From gene sequencing data analysis of neoantigens to the final production of a high-quality research-grade mRNA or peptide vaccine, our standard customized service timeline is typically 6-12 weeks, depending on the number of targets and the required quality level.

How do you ensure the immunogenicity of cancer vaccines?

We ensure immunogenicity through three main aspects: 1) Antigen selection (high-affinity prediction), 2) Delivery optimization (custom LNP or viral vectors), and 3) Adjuvant screening (offering various PRR ligands and adjuvant systems) to ensure effective antigen presentation and powerful T-cell activation.

How do you help us select the most suitable adjuvant for our project needs?

Adjuvant selection is critical. We offer comprehensive adjuvant screening and optimization services, including TLR agonists, oil-in-water emulsions, and aluminum salts, based on your vaccine type, target immunogenicity, desired immune response type (e.g., Th1 or Th2), and anticipated delivery system, ensuring maximal vaccine potency.

If my project requires combination therapy (e.g., vaccine + checkpoint inhibitor), can you provide support?

Yes, but only limited to preclinical research design and exploratory assessment. We provide in vitro combination efficacy models and in vivo synergistic effect assessments to guide your research direction. All services are strictly for research use.

Inquire About Creative Biolabs' Comprehensive Cancer Vaccine Services

Creative Biolabs leverages an advanced technological platform and profound expertise to offer researchers worldwide custom-tailored, high-quality, and highly efficient cancer vaccine development services. Our diverse portfolio is designed to meet your most intricate research needs, accelerating breakthroughs in cancer treatment.

Contact Our Expert Team

Featured Resources

Reference image of vaccine-resources-1, containing materials relevant to vaccine research and development.

Download Resources

Visual of vaccine-literature-1, representing academic or technical literature focused on vaccine studies.